Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 20/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932810 | 0.89 | CACNA1B (0.67) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL13932916 | 0.85 | CACNA1B (0.55) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL8230250 | 0.83 | CACNA1B (0.56) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL8233060 | 0.83 | CACNA1B (0.56) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL2188014 | 0.82 | CYP3A4 (0.52) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL13932903 | 0.81 | CACNA1B (0.57) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4269288 | 0.81 | CACNA1B (0.53) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4273754 | 0.79 | CACNA1B (0.53) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4273747 | 0.79 | CACNA1B (0.53) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4275429 | 0.79 | CACNA1B (0.53) | CACNA1BNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247442-B2 | Benzenesulfonamide compounds and their use | PURDUE PHARMA L.P. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247442-B2 | Benzenesulfonamide compounds and their use | PURDUE PHARMA L.P. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| WO-2007110449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE | EURO-CELTIQUE S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE | EURO-CELTIQUE S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | CACNA1E, CACNA1A, KCNN3 | CACNA1B 5/4885NR1I2 1307/4885CYP3A4 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.